請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/784
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄭貽生(Yi-Sheng Cheng) | |
dc.contributor.author | Yu-Hsuan Lee | en |
dc.contributor.author | 李昱璇 | zh_TW |
dc.date.accessioned | 2021-05-11T05:04:29Z | - |
dc.date.available | 2019-07-10 | |
dc.date.available | 2021-05-11T05:04:29Z | - |
dc.date.copyright | 2019-07-10 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-06-27 | |
dc.identifier.citation | Baum, B., Muley, L., Smolinski, M., Heine, A., Hangauer, D., and Klebe, G. (2010). Non-additivity of functional group contributions in protein-ligand binding: a comprehensive study by crystallography and isothermal titration calorimetry. J Mol Biol 397(4): 1042-1054.
Berman, H., Henrick, K. and Nakamura, H. (2003). Announcing the worldwide Protein Data Bank. Nat Struct Biol 10(12): 980. Bessman, M. J., Frick, D. N. and O’Handley, S. F. (1996). The MutT Proteins or ″Nudix″ Hydrolases, a Family of Versatile, Widely Distributed, ″housecleaning″ Enzymes. J Biol Chem 271(41): 25059-25062. Bissantz, C., Kuhn, B. and Stahl, M. (2010). A medicinal chemist's guide to molecular interactions. J Med Chem 53(14): 5061-5084. Brandt, T., Holzmann, N., Muley, L., Khayat, M., Wegscheid-Gerlach, C., Baum, B., Heine, A., Hangauer, D. and Klebe, G. (2011). Congeneric but still distinct: how closely related trypsin ligands exhibit different thermodynamic and structural properties. J Mol Biol 405(5): 1170-1187. Chodera, J. D. and Mobley, D. L. (2013). Entropy-enthalpy compensation: role and ramifications in biomolecular ligand recognition and design. Annu Rev Biophys 42: 121-142. Dullweber, F. D., Stubbs, M. T., Musil, D., Sturzebecher, J. and Klebe, G. (2001). Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition. J Mol Biol 313(3): 593-614. Dunitz, J.D. (2003). Win some, lose some: enthalpy-entropy compensation in weak intermolecular interactions. Chem Biol 2(11): 709-712. Emsley, P., Lohkamp, B., Scott, W. G. and Cowtan, K. (2010). Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66(Pt 4): 486-501. Rahm, F., Viklund, J., Tresaugues, L., Ellermann, M., Giese, A., Ericsson, U., Forsblom, R., Ginman, T., Gunther, J., Hallberg, K., Lindstrom, J., Persson, L.B., Silvander, C., Talagas, A., Diaz-Saez, L., Fedorov, O., Huber, K.V.M., Panagakou, I., Siejka, P., Gorjanacz, M., Bauser, M. and Andersson, M. (2018). Creation of a Novel Class of Potent and Selective MutT Homologue 1 (MTH1) Inhibitors Using Fragment-Based Screening and Structure Based Drug Design. J. Med. Chem. 2018, 61, 2533-2551. Gad, H., Koolmeister, T., Jemth, A. S., Eshtad, S., Jacques, S. A., Ström, C. E., Svensson, L. M., Schultz, N., Lundbäck, T., Einarsdottir, B. O., Saleh, A., Göktürk, C., Baranczewski, P., Svensson, R., Berntsson, R. P. A., Gustafsson, R., Strömberg, K., Sanjiv, K., JacquesCordonnier, M. C., Desroses, M., Gustavsson, A. L., Olofsson, R., Johansson, F., Homan, E. J., Loseva, O., Bräutigam, L., Johansson, L., Höglund, A., Hagenkort, A., Pham, T., Altun, M., Gaugaz, F. Z., Vikingsson, S., Evers, B., Henriksson, M., Vallin, K. S. A., Wallner, O. A., Hammarström, L. G. J., Wiita, E.; Almlöf, I., Kalderén, C., Axelsson, H., Djureinovic, T., Puigvert, J. C., Häggblad, M., Jeppsson, F., Martens, U., Lundin, C., Lundgren, B., Granelli, I., Jensen, A. J., Artursson, P., Nilsson, J. A., Stenmark, P., Scobie, M., Berglund, U. W. and Helleday, T. (2014). MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature 508(7495): 215-221. Geschwindner, S., Ulander, J. and Johansson, P. (2015). Ligand Binding Thermodynamics in Drug Discovery: Still a Hot Tip? J Med Chem 58(16): 6321-6335. Grunwald, E. and Steel, C. (1995). Solvent Reorganization and Thermodynamic Enthalpy-Entropy Compensation. J Am Chem Soc. 117:5687–5692 Huggins, D.J., Sherman, W. and Tidor, B. (2012). Rational approaches to improving selectivity in drug design. J Med Chem 55(4): 1424-1444. Kamiya, H. (2006). Recognition of nucleotide analogs containing the 7,8-dihydro-8-oxo structure by the human MTH1 protein. J. Biochem. 140, 843-849 Kettle, J. G., Alwan, H., Bista, M., Breed, J., Davies, N. L., Eckersley, K., Fillery, S., Foote, K. M., Goodwin, L., Jones, D. R., Kack, H., Lau, A., Nissink, J. W., Read, J., Scott, J. S., Taylor, B., Walker, G., Wissler, L. and Wylot, M. (2016). Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival. J. Med. Chem. 59, 2346−2361. King, N. M., Prabu-Jeyabalan, M., Bandaranayake, R. M., Nalam, M. N., Nalivaika, E. A., Ö zen, A., Haliloğlu, T., Yılmaz, N. K. and Schiffer, C. A. (2012). Extreme Entropy–Enthalpy Compensation in a Drug-Resistant Variant of HIV-1 Protease. ACS Chem. Biol.120702155441004. Klebe, G. (2015). Applying thermodynamic profiling in lead finding and optimization. Nat Rev Drug Discov 14(2): 95-110. Koshland, Jr., E., D. (1994). The key-lock theory and the induced fit theory. Angew. Chem. Int. Ed. Engl. 1994, 33, 2375–2378 Kuhn, B., Fuchs, J.E., Reutlinger, M., Stahl, M. and Taylor, N.R. (2011). Rationalizing tight ligand binding through cooperative interaction networks. J Chem Inf Model 51(12): 3180-3198. Kuhn, B., Guba, W., Banner, D., Bissantz, C., Ceccarelli, S., Haap, W., Körner, M., Kuglstatter, A., Lerner, C., Mattei, P., Neidhart, W., Pinard, E., Rudolph, M., Schulz-gasch, T., Woltering, T. and Stahl, M. (2016). A Real-World Perspective on Molecular Design. J Med Chem 59(9): 4087-4102. Lafont, V., Armstrong, A.A., Ohtaka, H., Kiso, Y., Mario, Amzel. L. and Freire, E. (2007). Compensating enthalpic and entropic changes hinder binding affinity optimization. Chem Biol Drug Disc. 69:413–422. Liou, G. Y. and Storz, P. (2010). Reactive oxygen species in cancer. Free Radic Res 44(5): 479-496. Luo, M., He, H., Kelley, M.R. and Georgiadis, M.M. (2010). Redox regulation of DNA repair: implications for human health and cancer therapeutic development. Antioxid. Redox Signaling 12, 1247− 1269. Maki, H., and Sekiguchi, M. (1992). MutT protein specifically hydrolyses a potent mutagenic substrate for DNA synthesis. Nature 355,273–275 Meyer, E. (1992). Internal water molecules and H-bonding in biological macromolecules: a review of structural features with functional implications. Protein Sci. 1, 1543-l 562. Mishima, M., Sakai, Y., Itoh, N., Kamiya, H., Furuichi, M., Takahashi, M., Yamagata, Y., Iwai, S., Nakabeppu, Y. and Shirakawa, M. (2004). Structure of human MTH1, a Nudix family hydrolase that selectively degrades oxidized purine nucleoside triphosphates. J Biol Chem 279(32): 33806-33815. Nakamura, T., Meshitsuka, S., Kitagawa, S., Abe, N., Yamada, J., Ishino, T., Nakano, H., Tsuzuki, T., Doi, T., Kobayashi, Y., Fujii, S., Sekiguchi, M. and Yamagata, Y. (2010). Structural and dynamic features of the MutT protein in the recognition of nucleotides with the mutagenic 8-oxoguanine base. J.Biol.Chem.285,444–452 Nissink, J. W., Bista, M., Breed, J., Carter, N., Embrey, K., Read, J. and WinterHolt, J. J. (2016). MTH1 Substrate Recognition--An Example of Specific Promiscuity. PLoS One 11(3): e0151154. Noble, M.E., Endicott, J.A. and Johnson, L.N. (2004). Protein Kinase Inhibitors: Insights into Drug Design from Structure. Science 2004, 303, 1800−1805. Olsson, T. S. G., Ladbury, J. E., Pitt, W. R. and Williams, M. A. (2011). Extent of enthalpy-entropy compensation in protein-ligand interactions. Protein Science. 2011; 20:1607–1618. Onufriev, A.V. and Alexov, E. (2013). Protonation and pK changes in protein-ligand binding. Q. Rev. Biophys. 46, 181−209. Qian, H. (1998). Entropy-enthalpy compensation: Conformational fluctuation and induced-fit. J Chem Phys. 109:10015–10017 Russo, M.T., Blasi, M.F., Chiera, F., Fortini, P., Degan, P., Macpherson, P., Furuichi, M., Nakabeppu, Y., Karran, P., Aquilina, G. and Bignami, M. (2004). The oxidized deoxynucleoside triphosphate pool is a significant contributor to genetic instability in mismatch repair-deficient cells. Mol.Cell.Biol. 24,465–474. Sakai, Y., Furuichi, M., Takahashi, M., Mishima, M., Iwai, S., Shirakawa, M. and Nakabeppu, Y. (2002). A molecular basis for the selective recognition of 2-hydroxy-dATP and 8-oxo-dGTP by human MTH1. J. Biol. Chem.277,8579–8587 Schnapp, G., Klein, T., Hoevels, Y., Bakker, R.A. and Nar, H. (2016). Comparative Analysis of Binding Kinetics and Thermodynamics of Dipeptidyl Peptidase-4 Inhibitors and Their Relationship to Structure. J Med Chem 59(16): 7466-7477. Sharp, K. (2001). Entropy-enthalpy compensation: fact or artifact? Protein Sci 10(3): 661-667. Storz, P. (2005). Reactive oxygen species in tumor progression. Front Biosci 10:1881–96. Svensson, L.M., Jemth, A.S., Desroses, M., Loseva, O., Helleday, T., Högbom, M. and Stenmark, P. (2011). Crystal structure of human MTH1 and the 8-oxo-dGMP product complex. FEBS Lett 585(16): 2617-2621. Tellinghuisen, J. A. (2003). study of statistical error in isothermal titration calorimetry. Anal Biochem. 2003; 321:79–88. Waz, S., Nakamura, T., Hirata, K., Koga-Ogawa, Y., Chirifu, M., Arimori, T., Tamada, T., Ikemizu, S., Nakabeppu, Y. and Yamagata, Y. (2017). Structural and Kinetic Studies of the Human Nudix Hydrolase MTH1 Reveal the Mechanism for Its Broad Substrate Specificity. J Biol Chem 292(7): 2785-2794. wwPDB consortium. Protein Data Bank: The single global archive for 3D macromolecular structure data jointly managed by the Worldwide Protein Data Bank. Nucleic Acid Res.2019; doi:10.1093/nar/gky949. Velazquez-Campoy, A., Kiso, Y. and Freire, E. (2001). The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. Arch Biochem Biophys;390:169–175. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/handle/123456789/784 | - |
dc.description.abstract | Mut T homolog 1 (MTH1) 為Nudix水解酶超家族的成員,在癌細胞的增生中扮演關鍵的角色。先前研究指出MTH1適合作為抗癌藥物的標靶,並已有MTH1抑制劑的體外以及體內成效被發表。本論文為深入探討MTH1-抑制劑複合體的結合機制,以高通量藥物片段篩選具有抑制MTH1的小分子,以其中一組作為骨架,進一步設計修飾2-氨基嘧啶衍生物共14個,依嘧啶環上5位碳乙基的有無分類為兩個群組,並分別解析MTH1與11個2-氨基嘧啶衍生物複合體結構,輔以生化及熱力學分析,以探討MTH1與抑制物複合體結合作用之多方位資訊。
根據已解出之MTH1與受質複合體結構,可將MTH1之活性口袋區初步劃分為三個特定區域。MTH1之受質8-oxo dGTP (8-Oxo-2’-deoxyguanosine-5’-Triphosphate)具有三部分官能基分別為鹼基,去氧核糖以及三磷酸,在鹼基部分主要由Asp119,Asp120及Trp117的側鏈鍵結,此區域也是這些抑制劑在結合口袋中的主要穩定作用力,旁側存在由多個疏水性胺基酸Phe72,Phe74及Phe139側鏈形成之空間,本實驗中將抑制劑的官能基延伸至由Phe72,Phe74,Phe139形成的空腔時,並無法提升抑制劑結合能力。從受質的8號位置氧原子位於Phe27與Met81的側鏈附近,且設計抑制劑亦與Phe27及Met81可形成凡得瓦力交互作用,本區將可提供與MTH1專一性結合。根據本研究系列合成抑制物之抑制效率分析,當抑制物延伸至受質之三磷酸的區域時,其結合能力降低三個級數,由Lys23,Glu52,Glu55,Glu56及Glu100組成的三磷酸結合區在催化水解反應時,會與金屬離子結合並形成水分子網絡,本區可作為未來延伸區域,以提高專一性結合。最後,本研究以受質結合區結構、熱力學分析及酵素動力學探討設計抑制劑的方式,將可作為未來在設計新穎抑制劑時參考依據。 | zh_TW |
dc.description.abstract | Mut T homolog 1 (MTH1) is a member of Nudix hydrolase superfamily and engages in proliferation of cancer cells as critical determinant. In previous study, it was proposed that MTH1 serves as ideal anticancer target for anticancer therapeutic development , and in vitro and in vivo efficacy were reported for several MTH1 inhibitors.
In this study, to elucidate the mechanism of MTH1-inhibitor complex formation extensively, high-throughput screening (HTS) was performed on fragment library intended to identify small molecule compound with moderate inhibitory activity against MTH1. From identified hits, one hit compound was utilized as scaffold and a series of 2-aminopyrimidine derivatives comprising 14 structurally-related compounds were subsequently synthesized based on HTS results. These 2-aminopyrimidine-based compounds are categorized into two groups based on the presence of ethyl substituent on pyrimidine ring. Explicitly, MTH1 complex structures bound with eleven 2-aminopyrimidine derivatives were obtained and supplemented with statistics from biochemical and thermodynamic analyses to complement the intricate binding interaction of MTH1-inhibitor complex from multiple aspects. Based on MTH1-substrate complex structure, the substrate binding pocket can be divided into three subregions which are occupied by base, deoxyribose and triphosphate group of substrate 8-oxo dGTP, respectively. In the base binding region, the bonds are formed by side chains of Asp119, Asp120 and Trp117 which are essential in binding of synthesized inhibitors in the binding pocket. Adjacent to the base binding motif, a minor cavity formed by side chains of hydrophobic residues Phe72, Phe74, Phe139 allows further exploration with substituents. However, no enhanced binding affinity was observed in exploring this cavity. Additionally, in the analysis of MTH1-inhibitor complex structures, it was observed that residues Phe27 and Met81 form van der Waals interactions selectively with synthesized compounds upon formation of complex. These residues sit in the proximity of 8-oxo group from substrate which was inferred to contribute to specificity of MTH1 through formation of favorable interactions. Intrinsically, as implied in structure-activity relationship study, incorporation of ligand moiety which occupies triphosphate binding region of MTH1 reduced binding affinity by three orders of magnitude. Structurally, triphosphate binding region constituted of Lys23, Glu52, Glu55, Glu56 and Glu100 facilitates catalysis of hydrolytic reaction through formation of water molecule network coordinated by metal ions. Therefore, it is indicated that this subregion can be further exploited for enhancement of specificity of inhibitors. In conclusion, through investigation of MTH1 substrate binding pocket with structural analysis, thermodynamic studies and enzyme kinetic analysis in this study, directions are provided for design of novel inhibitors in the future. | en |
dc.description.provenance | Made available in DSpace on 2021-05-11T05:04:29Z (GMT). No. of bitstreams: 1 ntu-108-R05b21025-1.pdf: 10532590 bytes, checksum: bdaa578b234bcffbd3ea341b185f4aff (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口試委員會審定書 i
致謝 ii Contents iii List of Figures vi List of Tables viii 中文摘要 ix Abstract x List of abbreviations xii Chapter 1 Introduction 1 1-1 Carcinogenesis: Distinguishing cancer cells from normal cells 1 1-1-1 ROS homeostasis in cancer development and apoptosis 1 1-1-2 Anticancer drug discovery exploiting ROS-mediated signaling pathways in cancer cell 2 1-2 Practical aspects in cancer therapeutic development 3 1-2-1 Identification and validation of molecular targets in cancer cell 3 1-2-2 High-throughput screening in searching for potential drug candidates and hit-to-lead optimization campaign 4 1-2-3 Biochemical and biophysical approaches in hit-to-lead optimization campaign 5 1-2-4 Thermodynamic profiles of protein-ligand complex formation 5 1-3 MutT homolog 1 (MTH1)- potential target for anticancer drug 7 1-3-1 Physiological function of MTH1 and ROS-modulated apoptosis 7 1-3-2 Protein structure of MTH1 8 1-3-3 MTH1 inhibitor development- perspectives and directions 9 1-4 Specific Aims and objectives 10 Chapter 2 Experimental section 12 2-1 Materials 12 2.2 Methods 12 2-2-1 Transformation 12 2-2-2 Protein Expression 13 2-2-3 Affinity Chromatography 13 2-2-4 IC50 Determination 14 2-2-5 Isothermal titration calorimetry 15 2-2-6 Size-exclusion chromatography 15 2-2-7 Crystallization and soaking 16 2-2-8 X-ray data collection 17 2-2-9 Model building and Refinement 17 Chapter 3 Results 19 3-1 MTH1 protein purification 19 3-1-1 Affinity Chromatography 19 3-1-2 Size-exclusion chromatography (SEC) 19 3-2 Determination of binding affinity profiles and structure-activity relationship (SAR) 20 3-2-1 Fragment-based drug screening and optimization performed with 2-aminopyrimidine-based scaffold 20 3-2-2 Binding affinity profile and SAR study of scaffold 1-derived compounds 21 3-2-3 Binding affinity profile of scaffold 2-derived compounds 22 3-3 Thermodynamic study on 2-aminopyrimidine-based compounds derived from scaffold 2 23 3-3-1 Enthalpy-driven binding of 2-aminopyrimidine-based compounds to MTH1 23 3-3-2 Phenomenon of Enthalpy-Entropy Compensation (EEC) 24 3-3-3 Rationalization of observed EEC phenomenon through insights provided by atomic model of MTH1 in complex with 2-aminopyrimidine-based compounds 25 3-4 Structural analysis of MTH1 complex structure bound with 2-aminopyrimidine -based compounds 28 3-4-1 Conserve binding mode of pyrimidine-based compounds in the binding site of MTH1 28 3-4-2 Pyrimidine moiety 29 3-4-3 R1 and R2-substituent 30 3-5 Superposition of MTH1 complexed with product 8-oxo dGMP and compound 29, 30 30 3-5-1 Absence of affinity gain with extended substituent toward the entry of binding pocket 31 3-6 Notable difference in interaction pattern of heterocyclic substituent unraveled by deviation in position occupied by ligand 32 Chapter 4 Discussion 34 4-1 Functional mechanism of MTH1 protein and structural relevance to selectivity toward its substrate 34 4-2 The binding energetics underlying complex formation 35 4-2-1 Intrinsic phenomenon of EEC hinders the elevation of binding affinity 36 4-2-2 Proposed theories for explanation of contradictory effect of enthalpic and entropic component of Gibbs binding free energy 37 4-3 Structure-aided ligand design: perspectives and opportunities 38 4-3-1 Binding pattern observed in published MTH1-ligand complexes 39 4-3-2 Overview of available space left unexplored in MTH1 binding pocket in regard of information derived from explored regions 41 Chapter 5 Conclusion 43 References 45 Tables and Figures 51 Appendices 91 | |
dc.language.iso | en | |
dc.title | 依受質結合區探討MTH1與抑制劑之交互作用研究 | zh_TW |
dc.title | Investigation of interaction between MTH1 and synthesized inhibitors based on substrate binding site | en |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 何孟樵(Meng-Chiao Ho),徐駿森(Chun-Hua Hsu) | |
dc.subject.keyword | Nudix水解?,抑制物,抗癌藥物, | zh_TW |
dc.subject.keyword | Nudix hydrolase superfamily,inhibitor,anticancer therapeutic agent, | en |
dc.relation.page | 104 | |
dc.identifier.doi | 10.6342/NTU201901016 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2019-06-28 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生命科學系 | zh_TW |
顯示於系所單位: | 生命科學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf | 10.29 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。